Introduction {#section1-1076029618764847}
============

The most important underlying mechanism of coronary artery disease is a progressive atherosclerotic process, which, along with intracoronary thrombus formation, may lead to an acute myocardial infarction (AMI).^[@bibr1-1076029618764847][@bibr2-1076029618764847][@bibr3-1076029618764847]--[@bibr4-1076029618764847]^ During thrombus formation, both platelet activation and thrombin generation with fibrin formation play important roles.^[@bibr2-1076029618764847],[@bibr5-1076029618764847],[@bibr6-1076029618764847]^ Thrombin generation in vivo is indicated by the conversion of prothrombin to thrombin with formation of fragments 1 + 2 (F1+2) and the formation of fibrin. Activation of the fibrinolytic system with conversion of plasminogen to plasmin degrades fibrin, resulting in degradation products like [d]{.smallcaps}-dimer, being an indicator of both ongoing coagulation and fibrinolysis. The endogenous thrombin potential (ETP) is a measure of the potential to generate thrombin ex vivo and has been suggested to be an informative method to determine the degree of hypercoagulability.^[@bibr7-1076029618764847]^

Studies have shown increased levels of prothrombotic markers in patients with myocardial infarction, being associated with myocardial injury and function^[@bibr8-1076029618764847],[@bibr9-1076029618764847]^ as well as clinical outcome.^[@bibr10-1076029618764847][@bibr11-1076029618764847][@bibr12-1076029618764847]--[@bibr13-1076029618764847]^ There is, however, limited knowledge on the association between the acute prothrombotic state and long-term clinical outcome in patients with ST-segment elevation myocardial infarction (STEMI). The aim of the present study was therefore to investigate whether plasma levels of the prothrombotic markers F1+2, [d]{.smallcaps}-dimer, and ETP measured in the acute phase of STEMI are associated with long-term clinical outcome.

Material and methods {#section2-1076029618764847}
====================

Study Population and Design {#section3-1076029618764847}
---------------------------

In a cross-sectional cohort study performed at Oslo University Hospital, Ullevål, a total of 987 patients with STEMI were included between 2007 and 2011, as previously described.^[@bibr8-1076029618764847],[@bibr14-1076029618764847]^ When admitted to the hospital, they were treated with primary percutaneous coronary intervention (PCI) according to the standard operating procedures. Patients below the age of 18 years and patients unwilling or unable to give written informed consent were not included, and patients on warfarin treatment were excluded from the present investigation. Of the patients included, 43% presented with an anterior infarction and significant stenosis was observed in 1, 2, and 3 vessels in 54%, 29%, and 17%, respectively.

Blood samples were collected between 8 and 10 [am]{.smallcaps} in the morning at a median time of 24 hours after onset of symptoms, 18 hours after the PCI procedure. All samples were taken after an overnight fast in order to standardize blood sampling and also to avoid any influence of diurnal variations and food intake. Routine blood samples were drawn at hospital admission, and samples for troponin T were measured after standardized time intervals. Clinical information was collected from hospital records and questionnaires acquired at the time of inclusion. The study was approved by the regional ethics committee, and all patients gave written informed consent.

Laboratory Methods {#section4-1076029618764847}
------------------

Citrated blood (0.129 M trisodium citrate in dilution 1:10) was centrifuged within 30 minutes at 2500*g* at 4°C and plasma kept frozen at −80°C until analyzed. Both F1+2 and [d]{.smallcaps}-dimer were determined by enzyme-linked immunosorbent assay (Asserachrom [d]{.smallcaps}-dimer; Stago Diagnostica, Ansiere, France and Enzygnost F1+2; Siemens, Marburg, Germany, respectively). Interassay coefficient of variation (CV) for F1+2 and [d]{.smallcaps}-dimer was 5.4% and 6.5%, respectively. The ETP was determined by the calibrated automated thrombogram assay according to the manufacturer's instruction as previously described in detail.^[@bibr8-1076029618764847]^ All experiments were run in duplicates, and the interassay CV was 6.0%. The C-reactive protein (CRP) was measured with kits from DRG Instruments (Marburg/Lahn, Germany), and CV was \<5%.

Electrochemiluminescence technology for quantitative measurement was used for repeated measures of TnT (third-generation cTroponinT, Elecsys 2010; Roche, Mannheim, Germany), and NT-proBNP was measured by Elecsys proBNP sandwich immunoassay on Elecsys 2010 (Roche Diagnostics, Indianapolis, Indiana), with interassay CV of 7% for both. Left ventricular ejection fraction (LVEF) was measured by echocardiography within 3 months after the AMI (n = 767).

Clinical Outcome {#section5-1076029618764847}
----------------

The primary outcome was a composite of all-cause mortality, reinfarction, stroke, unscheduled revascularization, or rehospitalization for heart failure, whichever occurred first. Secondary outcome was total mortality. All patients were followed from date of inclusion until December 2013, giving a median follow-up time of 4.6 years. End points were recorded by telephone call and cross-checked with hospital records. The hospital records were evaluated and adjudicated by an end point committee for each end point, before analyzing the results. Mortality end points were obtained from the Cause of Death Registry, administered by the Norwegian Institute of Public Health.

Statistics {#section6-1076029618764847}
----------

Continuous variables are presented as median values with 25, 75 percentiles and categorical variables as number or proportions. As most of the variables were skewed, nonparametric methods were used. Differences between groups were tested by Mann-Whitney *U* test for continuous variables and by Pearson χ^2^ test for categorical variables. Multivariate analyses were performed by logistic regression, adjusting for relevant covariates as appears from [Table 1](#table1-1076029618764847){ref-type="table"} and variables associated with the coagulation markers, as well as troponin T, previously reported to be associated with the coagulation markers.^[@bibr8-1076029618764847]^ The relatively low number of deaths restricted the number of variables included. Receiver operating characteristic (ROC) curve analysis with the corresponding area under the curve (AUC) with 95% confidence interval (CI) was performed to determine the overall performance of [d]{.smallcaps}-dimer. *P* values \<.05 were considered statistically significant. The SPSS software version 23.0 (SPSS Inc, Chicago, Illinois) was used.

###### 

Characteristics of the Total Study Population.^a^

![](10.1177_1076029618764847-table1)

                                                                  Total Population (n = 971)   Combined Events+ (n = 195)   Combined Events− (n = 776)   *P*
  --------------------------------------------------------------- ---------------------------- ---------------------------- ---------------------------- --------
  Age                                                             61 (24-94)                   65 (24, 94)                  60 (24, 90)                  \<.001
  Male sex                                                        780 (80)                     153 (79)                     627 (81)                     .463
  Current smokers                                                 459 (47)                     91 (47)                      368 (47)                     .826
  Previous CVD                                                    222 (23)                     53 (27)                      169 (22)                     .112
  Treated hypertension                                            329 (34)                     74 (38)                      255 (33)                     .180
  Treated diabetes mellitus                                       122 (12)                     32 (16)                      90 (12)                      .070
  BMI (kg/m^2^)                                                   26.6 (24.3, 29.2)            26.3 (24.2, 29.4)            26.6 (24.3, 29.1)            .779
  Prehospital thrombolysis                                        109 (11)                     15 (8)                       94 (12)                      .080
  Aspirin                                                         222 (23)                     63 (32)                      159 (21)                     \<.001
  Statins                                                         217 (22)                     55 (28)                      162 (21)                     .028
  Total cholesterol (mmol/L)                                      4.9 (4.1, 5.6)               4.7 (3.9, 5.7)               4.9 (4.2, 5.6)               .056
  HDL (mmol/L)                                                    1.07 (0.88, 1.30)            1.08 (0.88, 1.34)            1.06 (0.88, 1.27)            .392
  Triglycerides (mmol/L)                                          1.25 (0.89, 1.78)            1.22 (0.81, 1.72)            1.25 (0.90, 1.79)            .160
  CRP (mg/L)                                                      13.5 (7.0, 32.0)             14.8 (6.9, 36.2)             13.2 (7.0, 31.5)             .789
  Admission glucose (mmol/L)                                      7.4 (6.3, 9.0)               7.8 (6.5, 9.4)               7.3 (6.3, 8.8)               .007
  HbA~1c~ (%)                                                     5.9 (5.6, 6.3)               6.0 (5.7, 6.4)               5.9 (5.6, 6.2)               .085
  Peak troponin T (ng/L)                                          3850 (1730, 7160)            3900 (1440, 7530)            3845 (1815, 7135)            .635
  NT-proBNP (pmol/L)                                              31 (10, 118)                 50 (12, 181)                 28 (10, 107)                 .004
  LV ejection fraction (%)                                        49.2 (±9.18)                 46.7 (11.4)                  49.8 (8.5)                   .005
  Time from onset of symptoms to blood sampling (hours) (range)   24 (5, 118)                  24 (6, 96)                   24 (2, 264)                  .916

Abbreviations: BMI, body mass index; CRP, C-reactive protein; CVD, cardiovascular disease (previous myocardial infarction, percutaneous coronary intervention, or coronary artery bypass surgery); HDL, high-density lipoprotein cholesterol; LV, left ventricle.

^a^n = 971. Number (proportions) or median (25, 75 percentiles) are given. *P* values refer to differences between a group of patients with clinical events versus without.

Results {#section7-1076029618764847}
=======

A total of 987 patients were included and clinical end points were obtained from 971 (98.4%) patients. Sixteen patients were not reached by telephone or mail. The number of combined end points was 195, consisting of 62 deaths, 61 reinfarctions, 6 strokes, 52 unscheduled revascularizations, and 14 hospitalizations for heart failure. The number of total mortality was 79, of which 17 died after first having experienced a nonfatal event.

[Table 1](#table1-1076029618764847){ref-type="table"} shows the baseline characteristics of the study population (n = 971) and according to groupings of with or without combined end point. Patients with combined end points were older, they were more frequent users of aspirin and statins at hospital admission, and they had higher levels of admission glucose and NT-proBNP and lower LVEF. In the Supplemental Table a, results on groupings according to total mortality are shown. We have previously reported on significant associations between the measured biomarkers and levels of NT-proBNP and troponin T.^[@bibr8-1076029618764847]^

Prothrombotic Markers and Clinical Outcome {#section8-1076029618764847}
------------------------------------------

The prothrombotic markers as related to the clinical end points are shown in [Table 2](#table2-1076029618764847){ref-type="table"}. The levels of F1+2 and [d]{.smallcaps}-dimer were significantly higher with regard to both the combined end points (*P* = .012 and *P* = .026, respectively) and patients who later died (*P* \< .001, both). The levels of ETP were significantly lower with regard to both end points (*P* = .009, both; [Table 2](#table2-1076029618764847){ref-type="table"}).

###### 

Levels of F1+2, [d]{.smallcaps}-dimer, and ETP in the Total Population and as Related to Clinical Events.^a^

![](10.1177_1076029618764847-table2)

                                  Total Population    Combined Events+    Combined Events−    *P*1   Total Mortality+    Total Mortality−    *P*2
  ------------------------------- ------------------- ------------------- ------------------- ------ ------------------- ------------------- --------
  F1+2 (pmol/L)                   246 (178, 359)      265 (198, 395)      241 (173, 351)      .012   321 (206, 457)      242 (177, 353)      \<.001
  [d]{.smallcaps}-dimer (ng/mL)   456 (286, 801)      519 (319, 1012)     442 (285, 778)      .026   807 (470, 4695)     435 (280, 776)      \<.001
  ETP (nM·min)                    1564 (1366, 1740)   1504 (1335, 1697)   1576 (1372, 1749)   .009   1464 (1250, 1642)   1570 (1371, 1743)   .009

Abbreviation: ETP, endogenous thrombin potential; F1+2, fragments 1 + 2.

^a^Medians (25, 75 percentiles) are given. *P*1 values refer to difference between patients with and without clinical events; *P*2 values refer to differences between those who died and not).

When dividing the levels of F1+2, [d]{.smallcaps}-dimer, and ETP in quartiles, we observed significant trends of increasing number of both end points through quartiles of F1+2 and [d]{.smallcaps}-dimer ([Figure 1](#fig1-1076029618764847){ref-type="fig"}). When dichotomizing levels at median values of the total population ([Table 2](#table2-1076029618764847){ref-type="table"}), significantly increased risk of events was observed in univariate analyses (combined end point *P* = .020 and *P* = .010, respectively, and total mortality *P* \< .001 for both; [Table 3](#table3-1076029618764847){ref-type="table"}). When adjusting for relevant covariates (age, sex, admission glucose, NT-proBNP, and peak troponin T, aspirin, and statin), the significance was lost for the composite end points, whereas [d-]{.smallcaps}dimer was still significantly associated with total mortality with an odds ratio of 2.01 (95% CI, 1.06-3.83; *P* = .034) and F1+2 of borderline significance (*P* = .090; [Table 3](#table3-1076029618764847){ref-type="table"}). The opposite picture was seen for ETP with reduced risk of both end points through quartiles ([Figure 1](#fig1-1076029618764847){ref-type="fig"}). Dichotomized at median, significantly reduced risk was observed in patients with ETP levels above median, however, statistically significant only with respect to the primary end point ([Table 3](#table3-1076029618764847){ref-type="table"}). The results did not change when adding CRP levels, prehospital thrombolysis, and the time from onset of symptoms to blood sampling to the models.

![Levels of fragments 1 + 2 (F1+2), [d]{.smallcaps}-dimer, and endogenous thrombin potential (ETP) in quartiles as related to first clinical event (upper panel) and total mortality (lower panel). *P* values refer to trends across quartiles. F1+2: Q1 \< 178, Q2 ≥ 179-246, Q3 ≥ 247-356, Q4 ≥ 357; [d]{.smallcaps}-dimer: Q1 \< 287, Q2 ≥ 288-456, Q3 ≥ 457-796, Q4 ≥ 797; ETP: Q1 \< 136, Q2 ≥ 1367-1564, Q3 ≥ 1565-1743, Q4 ≥ 1744.](10.1177_1076029618764847-fig1){#fig1-1076029618764847}

###### 

Crude and Multivariate Associations Between the Markers of Hypercoagulability and Clinical Events (A) or Total Mortality (B).

![](10.1177_1076029618764847-table3)

                           OR      Crude 95% CI   *P*      OR      Adjusted^a^ 95% CI   *P*
  ------------------------ ------- -------------- -------- ------- -------------------- ------
  Combined events                                                                       
   F1+2                    1.457   1.060-2.003    .020     1.337   0.936-1.909          .110
   [d]{.smallcaps}-dimer   1.520   1.105-2.090    .010     1.179   0.814-1.706          .384
   ETP                     0.641   0.462-0.890    .008     0.688   0.484-0.980          .038
  Total mortality                                                                       
   F1+2                    2.718   1.631-4.527    \<.001   1.664   0.924-2.995          .090
   [d]{.smallcaps}-dimer   3.972   2.284-6.908    \<.001   2.010   1.055-3.829          .034
   ETP                     0.543   0.330-0.895    .017     0.824   0.469-1.449          .502

Abbreviation: CI, confidence interval; ETP, endogenous thrombin potential; F1+2, fragments 1 + 2; OR, odds ratio.

^a^Adjusted for age, gender, admission glucose, NT-ProBNP, troponin T markers, use of aspirin, and statins at hospital admission.

The ROC curve for [d]{.smallcaps}-dimer in the prognosis of mortality is visualized in [Figure 2](#fig2-1076029618764847){ref-type="fig"}, showing an AUC of 0.700 (95% CI, 0.640-0.758; *P* \< .001). The AUC of NT-proBNP, which is known to be a strong predictor of mortality, is shown in comparison (AUC: 0.702; 95% CI, 0.644-0.760).

![Receiver operating characteristic curves for [d]{.smallcaps}-dimer and NT-proBNP as related to total mortality.](10.1177_1076029618764847-fig2){#fig2-1076029618764847}

Discussion {#section9-1076029618764847}
==========

The main findings in this study on patients with STEMI were that biomarkers of hypercoagulability, that is, F1+2, [d]{.smallcaps}-dimer, and ETP, were all associated with clinical outcome after 4.6 years in univariate analyses. When adjusting for relevant covariates, [d]{.smallcaps}-dimer was still significantly associated with a 2-fold increased risk of death and ETP with reduced risk of first composite end point. It should be emphasized that patients on oral anticoagulation were excluded from the study, and medication like aspirin and statins, which might have influenced the results, were included in the multivariate analyses.

[d]{.smallcaps}-dimer is known to be an acute-phase protein and thus unspecific; however, the association with mortality was still significant after adjustment for CRP. The AUC of 0.700 is indicative of [d]{.smallcaps}-dimer to be related to the prognosis, although only fair, as good as for NT-proBNP.

The relationship between [d]{.smallcaps}-dimer and clinical outcome has previously been reported in patients with cardiovascular disease. In patients with unstable angina, some early reports in smaller cohorts showed [d]{.smallcaps}-dimer to be associated with a high risk of future events.^[@bibr11-1076029618764847],[@bibr15-1076029618764847]^ In patients with an AMI, there are limited reports, especially with long-term follow-up. Results are diverging, also for the time of blood sampling and follow-up time. In a study by Erkol et al, [d]{.smallcaps}-dimer assessed on admission in a relatively large AMI population was shown to have no independent predictivity for long-term outcome.^[@bibr16-1076029618764847]^ On the contrary, and in line with our findings, the Horizon study with long-term follow-up of patients with AMI over 3 years demonstrated that [d]{.smallcaps}-dimer measured very early did predict future clinical outcome, whereas [d]{.smallcaps}-dimer measured at discharge from hospital was not associated with long-term prognosis.^[@bibr17-1076029618764847]^ In another study, [d]{.smallcaps}-dimer measured in the stable phase 2 months after AMI was shown to be independently associated with cardiovascular outcome, including cardiovascular death after 26 months, indicating an increased prothrombotic state long term after the initial event.^[@bibr17-1076029618764847]^

The mechanism behind the association between [d]{.smallcaps}-dimer and death may be related to the thrombogenic burden, represented by fibrin formation and turnover, clinically indicative of coronary thrombus and AMI. [d]{.smallcaps}-dimer has been reported to be of importance for myocardial necrosis and function after AMI. In the present population, we have previously reported that markers of thrombin generation were associated with myocardial necrosis and impaired left ventricular function.^[@bibr8-1076029618764847]^ Furthermore, Choi et al reported, in their study on 208 patients with STEMI, [d]{.smallcaps}-dimer levels on admission to be associated with larger infarct size, greater area at risk, and lower myocardial salvage index, evaluated by cardiac magnetic resonance 3 days after PCI treatment.^[@bibr18-1076029618764847]^

As for F1+2 which more directly reflects thrombin generation in vivo, there are limited data with respect to clinical events. In our study, F1+2 was strongly associated with both the primary end point and total mortality; however, after adjusting for covariates, of which age seemed to be the most important (data not shown), the significance was lost. In a small study of 68 patients, F1+2 measured 24 hours after an index STEMI, similar to ours, was shown to predict clinical outcome after 6 weeks.^[@bibr19-1076029618764847]^

In our study, ex vivo thrombin generation, assessed by ETP, was shown to be inversely associated with the primary end point, also after adjustments for covariates. We have previously shown an inverse relation between in vivo and ex vivo thrombin generation in the present population,^[@bibr8-1076029618764847]^ that is, as also reflected in the present findings. In accordance with our results, the large LURIC study on patients with AMI showed ETP to be inversely associated with cardiovascular events after a median of 10-year follow-up.^[@bibr20-1076029618764847]^ In that study, however, blood sampling was performed between 1 day and 4 weeks after AMI. Also in line with our result, Smid et al showed low ETP levels alone to be insignificantly associated with clinical end points; however, in combination with high [d]{.smallcaps}-dimer, significantly elevated risk for thrombotic cardiovascular events after 12 months was shown.^[@bibr21-1076029618764847]^ This somewhat strange finding of ETP being inversely related to risk of new clinical events is not easily explained. However, the high in vivo thrombin generation, shown by the levels of F1+2 and [d]{.smallcaps}-dimer, may contribute to an exhaustion phenomenon, especially during an acute situation, implicating less potential to generate thrombin ex vivo. In addition, as discussed by Smid et al, several plasma coagulation factors may influence on the determination of ETP, of which tissue factor pathway inhibitor seems to be most important.^[@bibr21-1076029618764847]^ These assumptions are, however, in contrast to the findings in a small study on patients with ACS, in which ETP was shown not to be related to recurrent events,^[@bibr22-1076029618764847]^ and Attanasio et al showed ETP to be positively associated with cardiovascular death after 2 years in 292 patients initially having an ACS and blood sampling within 12 to 24 hours.^[@bibr23-1076029618764847]^

Nevertheless, the hypercoagulable state shown to be present in the acute phase of STEMI might indicate a role for long-term anticoagulation as shown in earlier studies with warfarin^[@bibr24-1076029618764847],[@bibr25-1076029618764847]^ and the recent study with rivaroxaban in addition to aspirin.^[@bibr26-1076029618764847]^ However, confirmatory studies are needed before any cutoff value of [d]{.smallcaps}-dimer for potentially initiating treatment can be discussed.

Limitations {#section10-1076029618764847}
-----------

Single blood sampling prevented us from studying the initial time course of the measured markers. We do not know whether we have captured the real peak values of the variables or transient changes due to the variability in the time frame from onset of symptoms to blood sampling. However, the results did not change when time from symptom onset was included into the multivariate models. Our cohort of patients with STEMI was a low-risk population with few complications, and this fact may have influenced the results.

All patients in our study received heparin during the PCI procedure approximately 16 to 20 hours before blood sampling. Although any influence of heparin seems unlikely, we cannot completely exclude that small amounts of heparin were remaining.

Conclusion {#section11-1076029618764847}
==========

The hypercoagulable state in the acute phase of a STEMI seems to be of significant importance for future clinical outcome, especially for mortality. Thus, anticoagulant treatment after AMI might still be discussed.
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